In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

Arsenal Bio, one of the few cell therapy companies able to raise significant capital amid a prolonged downturn, has laid just ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Researchers at Tel Aviv University have developed a new approach for using locked nucleic acids (LNAs)—a particularly stable ...

Academic, industry, and FDA collaboration is key to personalized treatment manufacturing, says Aldevron’s Max Sellman at BPI this week.

Researchers in Berlin have used base editing to repair mutations that cause the kidney disorder ADPKD in cells from both mice ...

A 57-year-old homemaker, Ms. A, began occasionally losing items or struggling to recall people’s names a year ago. She ...

A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others ...